Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Adipose Tissue | 28 | 2019 | 327 | 5.650 |
Why?
|
Stem Cells | 11 | 2015 | 292 | 2.370 |
Why?
|
Cell Differentiation | 20 | 2017 | 436 | 2.030 |
Why?
|
Adipocytes | 13 | 2015 | 79 | 1.820 |
Why?
|
Stromal Cells | 11 | 2013 | 70 | 1.660 |
Why?
|
Cell Culture Techniques | 7 | 2013 | 165 | 1.240 |
Why?
|
Stem Cell Transplantation | 3 | 2015 | 203 | 1.090 |
Why?
|
Surgery, Plastic | 3 | 2019 | 26 | 0.990 |
Why?
|
Lipectomy | 5 | 2017 | 9 | 0.990 |
Why?
|
Mesenchymal Stem Cell Transplantation | 4 | 2015 | 75 | 0.960 |
Why?
|
Mesenchymal Stem Cells | 5 | 2017 | 161 | 0.900 |
Why?
|
Osteogenesis | 6 | 2016 | 75 | 0.900 |
Why?
|
Wound Healing | 4 | 2013 | 182 | 0.900 |
Why?
|
Mammaplasty | 2 | 2019 | 27 | 0.860 |
Why?
|
Tissue Engineering | 5 | 2015 | 608 | 0.830 |
Why?
|
Spheroids, Cellular | 3 | 2013 | 28 | 0.830 |
Why?
|
Regenerative Medicine | 3 | 2015 | 187 | 0.740 |
Why?
|
Regeneration | 5 | 2017 | 167 | 0.720 |
Why?
|
Cells, Cultured | 14 | 2017 | 799 | 0.710 |
Why?
|
Buttocks | 1 | 2019 | 5 | 0.710 |
Why?
|
Embolism, Fat | 1 | 2019 | 2 | 0.710 |
Why?
|
Workload | 1 | 2019 | 38 | 0.690 |
Why?
|
Burnout, Professional | 1 | 2019 | 44 | 0.660 |
Why?
|
Cell Separation | 3 | 2017 | 86 | 0.640 |
Why?
|
Humans | 43 | 2019 | 29093 | 0.630 |
Why?
|
Neovascularization, Physiologic | 4 | 2013 | 106 | 0.620 |
Why?
|
Adipogenesis | 6 | 2016 | 26 | 0.590 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 33 | 0.590 |
Why?
|
Collagen | 3 | 2012 | 217 | 0.560 |
Why?
|
Animals | 21 | 2015 | 7297 | 0.540 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2013 | 57 | 0.520 |
Why?
|
Immunocompromised Host | 1 | 2014 | 43 | 0.510 |
Why?
|
Adult Stem Cells | 2 | 2011 | 24 | 0.480 |
Why?
|
Proteome | 2 | 2013 | 34 | 0.470 |
Why?
|
Subcutaneous Fat | 2 | 2016 | 42 | 0.450 |
Why?
|
Burns | 2 | 2017 | 97 | 0.440 |
Why?
|
Cell Movement | 3 | 2012 | 161 | 0.440 |
Why?
|
Tissue Scaffolds | 3 | 2012 | 386 | 0.430 |
Why?
|
Chondroitin Sulfates | 1 | 2012 | 22 | 0.430 |
Why?
|
Guided Tissue Regeneration | 1 | 2012 | 36 | 0.420 |
Why?
|
Nervous System Physiological Phenomena | 1 | 2011 | 5 | 0.410 |
Why?
|
Biocompatible Materials | 2 | 2012 | 210 | 0.400 |
Why?
|
Culture Media | 2 | 2012 | 39 | 0.400 |
Why?
|
Risk Management | 1 | 2011 | 29 | 0.390 |
Why?
|
Induced Pluripotent Stem Cells | 1 | 2010 | 13 | 0.370 |
Why?
|
Diabetes Mellitus | 2 | 2011 | 366 | 0.370 |
Why?
|
Stem Cell Niche | 1 | 2010 | 25 | 0.370 |
Why?
|
Breast Neoplasms | 4 | 2019 | 666 | 0.360 |
Why?
|
Multipotent Stem Cells | 2 | 2007 | 15 | 0.360 |
Why?
|
Mesentery | 2 | 2008 | 5 | 0.350 |
Why?
|
Drug Delivery Systems | 1 | 2010 | 92 | 0.350 |
Why?
|
Flow Cytometry | 6 | 2017 | 171 | 0.340 |
Why?
|
Transplantation, Autologous | 3 | 2019 | 78 | 0.340 |
Why?
|
Surface-Active Agents | 1 | 2008 | 4 | 0.330 |
Why?
|
Poloxamer | 1 | 2008 | 4 | 0.330 |
Why?
|
Microcirculation | 1 | 2008 | 61 | 0.320 |
Why?
|
Regional Blood Flow | 1 | 2008 | 82 | 0.320 |
Why?
|
Organ Transplantation | 1 | 2009 | 65 | 0.320 |
Why?
|
Culture Media, Serum-Free | 2 | 2008 | 15 | 0.320 |
Why?
|
Mastectomy | 2 | 2019 | 59 | 0.320 |
Why?
|
Rats | 8 | 2013 | 1604 | 0.320 |
Why?
|
Cell Transplantation | 2 | 2009 | 63 | 0.300 |
Why?
|
Mice | 8 | 2015 | 2368 | 0.290 |
Why?
|
Reconstructive Surgical Procedures | 2 | 2019 | 190 | 0.280 |
Why?
|
Adult | 11 | 2019 | 8420 | 0.280 |
Why?
|
Antigens, Surface | 1 | 2005 | 19 | 0.260 |
Why?
|
Chondrogenesis | 3 | 2012 | 18 | 0.250 |
Why?
|
Gene Expression Profiling | 1 | 2005 | 320 | 0.230 |
Why?
|
RNA, Messenger | 3 | 2016 | 514 | 0.220 |
Why?
|
Pericytes | 2 | 2013 | 28 | 0.210 |
Why?
|
Middle Aged | 9 | 2019 | 10829 | 0.210 |
Why?
|
Cell Line | 5 | 2017 | 449 | 0.200 |
Why?
|
Fibronectins | 3 | 2017 | 34 | 0.200 |
Why?
|
Tissue and Organ Harvesting | 1 | 2001 | 35 | 0.190 |
Why?
|
Sciatic Neuropathy | 1 | 2010 | 15 | 0.190 |
Why?
|
Omentum | 1 | 2010 | 26 | 0.190 |
Why?
|
Nerve Regeneration | 1 | 2010 | 40 | 0.190 |
Why?
|
Bone Marrow Transplantation | 1 | 2010 | 65 | 0.190 |
Why?
|
Time Factors | 4 | 2011 | 2001 | 0.180 |
Why?
|
Esthetics | 1 | 2019 | 11 | 0.180 |
Why?
|
Journal Impact Factor | 1 | 2019 | 9 | 0.180 |
Why?
|
Female | 12 | 2019 | 18164 | 0.170 |
Why?
|
Rats, Sprague-Dawley | 3 | 2012 | 747 | 0.170 |
Why?
|
Documentation | 1 | 2019 | 32 | 0.170 |
Why?
|
Male | 9 | 2017 | 17807 | 0.170 |
Why?
|
Cell Lineage | 4 | 2009 | 67 | 0.170 |
Why?
|
Electronic Health Records | 1 | 2019 | 118 | 0.160 |
Why?
|
Periodicals as Topic | 1 | 2019 | 95 | 0.160 |
Why?
|
Tissue Preservation | 2 | 2011 | 5 | 0.160 |
Why?
|
Fluorescein | 1 | 2017 | 1 | 0.150 |
Why?
|
Lymphatic System | 1 | 2017 | 2 | 0.150 |
Why?
|
Lymphedema | 1 | 2017 | 4 | 0.150 |
Why?
|
Cicatrix | 1 | 2017 | 36 | 0.150 |
Why?
|
Cell Proliferation | 3 | 2009 | 573 | 0.150 |
Why?
|
Treatment Outcome | 3 | 2019 | 3099 | 0.150 |
Why?
|
Survival Rate | 1 | 2019 | 795 | 0.150 |
Why?
|
Adipocytes, White | 1 | 2016 | 2 | 0.150 |
Why?
|
Thermogenesis | 1 | 2016 | 4 | 0.150 |
Why?
|
Aromatase | 2 | 2006 | 6 | 0.140 |
Why?
|
BRCA1 Protein | 2 | 2006 | 10 | 0.140 |
Why?
|
Mesoderm | 3 | 2006 | 14 | 0.140 |
Why?
|
Cell Survival | 2 | 2014 | 272 | 0.140 |
Why?
|
Rats, Nude | 2 | 2013 | 38 | 0.140 |
Why?
|
Neovascularization, Pathologic | 2 | 2013 | 81 | 0.140 |
Why?
|
Pressure Ulcer | 1 | 2015 | 6 | 0.130 |
Why?
|
Bone Marrow Cells | 2 | 2017 | 114 | 0.130 |
Why?
|
Ventricular Function, Right | 1 | 2015 | 15 | 0.130 |
Why?
|
Achievement | 1 | 2015 | 3 | 0.130 |
Why?
|
Ventricular Dysfunction, Right | 1 | 2015 | 12 | 0.130 |
Why?
|
Dyspnea | 1 | 2015 | 30 | 0.130 |
Why?
|
Awards and Prizes | 1 | 2015 | 11 | 0.130 |
Why?
|
Efficiency | 1 | 2015 | 16 | 0.130 |
Why?
|
Mitochondria | 1 | 2016 | 174 | 0.130 |
Why?
|
Muscle, Skeletal | 3 | 2013 | 494 | 0.130 |
Why?
|
Skin | 2 | 2015 | 203 | 0.120 |
Why?
|
Fellowships and Scholarships | 1 | 2015 | 50 | 0.120 |
Why?
|
Gene Expression Regulation | 3 | 2017 | 481 | 0.120 |
Why?
|
Postoperative Complications | 1 | 2019 | 670 | 0.120 |
Why?
|
Disease Models, Animal | 3 | 2013 | 980 | 0.120 |
Why?
|
Societies, Medical | 1 | 2015 | 149 | 0.120 |
Why?
|
Cell Hypoxia | 2 | 2011 | 39 | 0.120 |
Why?
|
Risk Assessment | 1 | 2019 | 1305 | 0.120 |
Why?
|
Paracrine Communication | 1 | 2013 | 8 | 0.120 |
Why?
|
Culture Media, Conditioned | 1 | 2013 | 52 | 0.120 |
Why?
|
Immunomodulation | 1 | 2013 | 30 | 0.120 |
Why?
|
Young Adult | 2 | 2017 | 2402 | 0.110 |
Why?
|
NF-kappa B | 1 | 2013 | 75 | 0.110 |
Why?
|
Osteocytes | 1 | 2013 | 4 | 0.110 |
Why?
|
Calcification, Physiologic | 1 | 2013 | 9 | 0.110 |
Why?
|
Extracellular Matrix Proteins | 2 | 2010 | 40 | 0.110 |
Why?
|
Retina | 1 | 2013 | 50 | 0.110 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2013 | 93 | 0.110 |
Why?
|
Cell Growth Processes | 1 | 2012 | 9 | 0.110 |
Why?
|
Ascorbic Acid | 1 | 2012 | 21 | 0.110 |
Why?
|
Aged | 4 | 2018 | 9487 | 0.110 |
Why?
|
Tumor Stem Cell Assay | 1 | 2011 | 12 | 0.110 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 248 | 0.100 |
Why?
|
Cryopreservation | 1 | 2011 | 42 | 0.100 |
Why?
|
Random Allocation | 1 | 2012 | 213 | 0.100 |
Why?
|
Transplantation, Heterologous | 1 | 2011 | 121 | 0.100 |
Why?
|
Neuropeptides | 1 | 2011 | 19 | 0.100 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2012 | 100 | 0.100 |
Why?
|
Mice, Nude | 1 | 2011 | 276 | 0.100 |
Why?
|
Tendon Injuries | 1 | 2011 | 36 | 0.100 |
Why?
|
Survival Analysis | 1 | 2011 | 440 | 0.100 |
Why?
|
Cell Aggregation | 1 | 2010 | 3 | 0.090 |
Why?
|
Hepatocyte Growth Factor | 1 | 2010 | 5 | 0.090 |
Why?
|
Transgenes | 1 | 2010 | 45 | 0.090 |
Why?
|
Chemokines | 1 | 2010 | 35 | 0.090 |
Why?
|
Organ Culture Techniques | 1 | 2010 | 38 | 0.090 |
Why?
|
Mass Spectrometry | 1 | 2010 | 99 | 0.090 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 152 | 0.090 |
Why?
|
Lung Neoplasms | 1 | 2013 | 384 | 0.090 |
Why?
|
P-Selectin | 1 | 2009 | 10 | 0.090 |
Why?
|
Graft vs Host Disease | 1 | 2009 | 18 | 0.090 |
Why?
|
Promoter Regions, Genetic | 2 | 2006 | 212 | 0.080 |
Why?
|
Immunohistochemistry | 4 | 2016 | 519 | 0.080 |
Why?
|
Inflammation | 2 | 2011 | 507 | 0.080 |
Why?
|
Isotonic Solutions | 1 | 2008 | 4 | 0.080 |
Why?
|
Extracellular Matrix | 2 | 2011 | 226 | 0.080 |
Why?
|
Nanostructures | 1 | 2008 | 16 | 0.080 |
Why?
|
Biomimetic Materials | 1 | 2008 | 14 | 0.080 |
Why?
|
Ischemia | 1 | 2009 | 92 | 0.080 |
Why?
|
Cell Adhesion Molecules | 1 | 2008 | 45 | 0.080 |
Why?
|
Immunophenotyping | 3 | 2017 | 49 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 1 | 2013 | 871 | 0.080 |
Why?
|
Blood Vessels | 1 | 2008 | 47 | 0.080 |
Why?
|
Graft Rejection | 1 | 2009 | 149 | 0.080 |
Why?
|
Administration, Topical | 1 | 2008 | 130 | 0.080 |
Why?
|
Tissue Donors | 1 | 2009 | 167 | 0.080 |
Why?
|
Graft Survival | 1 | 2009 | 228 | 0.080 |
Why?
|
Hemodynamics | 1 | 2008 | 148 | 0.080 |
Why?
|
History, 20th Century | 2 | 2019 | 68 | 0.080 |
Why?
|
Serum | 1 | 2007 | 20 | 0.070 |
Why?
|
Models, Biological | 1 | 2009 | 373 | 0.070 |
Why?
|
Antigens, Differentiation | 1 | 2005 | 21 | 0.070 |
Why?
|
Telomerase | 1 | 2005 | 21 | 0.070 |
Why?
|
Ovarian Neoplasms | 1 | 2005 | 87 | 0.060 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2005 | 60 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2005 | 155 | 0.060 |
Why?
|
Osteoblasts | 3 | 2016 | 46 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2005 | 136 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2005 | 141 | 0.060 |
Why?
|
Protein Binding | 2 | 2017 | 199 | 0.060 |
Why?
|
Biomedical Engineering | 1 | 2001 | 23 | 0.050 |
Why?
|
Obesity | 3 | 2016 | 1063 | 0.050 |
Why?
|
S100 Proteins | 1 | 2010 | 18 | 0.050 |
Why?
|
Equipment Design | 1 | 2001 | 167 | 0.050 |
Why?
|
Recovery of Function | 1 | 2010 | 190 | 0.040 |
Why?
|
Phenotype | 2 | 2013 | 629 | 0.040 |
Why?
|
Mastectomy, Radical | 1 | 2018 | 1 | 0.040 |
Why?
|
Publishing | 1 | 2019 | 57 | 0.040 |
Why?
|
Mastectomy, Segmental | 1 | 2018 | 23 | 0.040 |
Why?
|
Cell Shape | 2 | 2008 | 26 | 0.040 |
Why?
|
Cell Line, Tumor | 2 | 2013 | 680 | 0.040 |
Why?
|
Skin Physiological Phenomena | 1 | 2017 | 7 | 0.040 |
Why?
|
Isothiocyanates | 1 | 2017 | 6 | 0.040 |
Why?
|
Axilla | 1 | 2017 | 15 | 0.040 |
Why?
|
Microsurgery | 1 | 2017 | 19 | 0.040 |
Why?
|
Glycosyltransferases | 1 | 2017 | 3 | 0.040 |
Why?
|
L-Selectin | 1 | 2017 | 3 | 0.040 |
Why?
|
Intraoperative Care | 1 | 2017 | 48 | 0.040 |
Why?
|
Glycosylation | 1 | 2017 | 15 | 0.040 |
Why?
|
E-Selectin | 1 | 2017 | 20 | 0.040 |
Why?
|
Polysaccharides | 1 | 2017 | 13 | 0.040 |
Why?
|
Neuraminidase | 1 | 2017 | 10 | 0.040 |
Why?
|
Image Enhancement | 1 | 2017 | 70 | 0.040 |
Why?
|
Glycoproteins | 1 | 2017 | 34 | 0.040 |
Why?
|
Ligands | 1 | 2017 | 81 | 0.040 |
Why?
|
Cell Adhesion | 1 | 2017 | 103 | 0.040 |
Why?
|
Adipocytes, Brown | 1 | 2016 | 2 | 0.040 |
Why?
|
Cell Respiration | 1 | 2016 | 21 | 0.040 |
Why?
|
STAT3 Transcription Factor | 1 | 2016 | 22 | 0.040 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 36 | 0.040 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 36 | 0.040 |
Why?
|
Phosphoproteins | 1 | 2016 | 54 | 0.040 |
Why?
|
Databases, Factual | 1 | 2017 | 332 | 0.030 |
Why?
|
Up-Regulation | 1 | 2016 | 183 | 0.030 |
Why?
|
Blotting, Western | 1 | 2016 | 281 | 0.030 |
Why?
|
Adolescent | 2 | 2016 | 3254 | 0.030 |
Why?
|
Tomography, Spiral Computed | 1 | 2015 | 18 | 0.030 |
Why?
|
Authorship | 1 | 2015 | 8 | 0.030 |
Why?
|
Peer Review, Research | 1 | 2015 | 6 | 0.030 |
Why?
|
Financing, Organized | 1 | 2015 | 14 | 0.030 |
Why?
|
Bibliometrics | 1 | 2015 | 9 | 0.030 |
Why?
|
History, 21st Century | 1 | 2015 | 48 | 0.030 |
Why?
|
Mentors | 1 | 2015 | 29 | 0.030 |
Why?
|
Echocardiography | 1 | 2015 | 140 | 0.030 |
Why?
|
Fibroblasts | 2 | 2008 | 103 | 0.030 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 159 | 0.030 |
Why?
|
Program Evaluation | 1 | 2015 | 175 | 0.030 |
Why?
|
Faculty, Medical | 1 | 2015 | 69 | 0.030 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2013 | 27 | 0.030 |
Why?
|
Retinal Vessels | 1 | 2013 | 18 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2013 | 158 | 0.030 |
Why?
|
Reference Standards | 1 | 2013 | 30 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2015 | 493 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2013 | 54 | 0.030 |
Why?
|
Cohort Studies | 1 | 2017 | 1687 | 0.030 |
Why?
|
Diabetic Retinopathy | 1 | 2013 | 64 | 0.030 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 90 | 0.030 |
Why?
|
Signal Transduction | 1 | 2016 | 666 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2013 | 199 | 0.030 |
Why?
|
Oxygen | 1 | 2013 | 139 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 249 | 0.030 |
Why?
|
Prospective Studies | 1 | 2017 | 2019 | 0.030 |
Why?
|
Chondrocytes | 2 | 2003 | 71 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2011 | 62 | 0.030 |
Why?
|
Exercise | 1 | 2016 | 591 | 0.020 |
Why?
|
Scoliosis | 1 | 2010 | 23 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2010 | 56 | 0.020 |
Why?
|
Antigens, CD | 1 | 2010 | 100 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2015 | 2108 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2010 | 454 | 0.020 |
Why?
|
Pseudopodia | 1 | 2008 | 2 | 0.020 |
Why?
|
Anthraquinones | 1 | 2008 | 5 | 0.020 |
Why?
|
Selectins | 1 | 2008 | 2 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2008 | 9 | 0.020 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2008 | 13 | 0.020 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 17 | 0.020 |
Why?
|
Cell Count | 1 | 2008 | 50 | 0.020 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2008 | 41 | 0.020 |
Why?
|
Cell Cycle | 1 | 2008 | 69 | 0.020 |
Why?
|
Liposarcoma | 1 | 2007 | 4 | 0.020 |
Why?
|
Lipoma | 1 | 2007 | 8 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2008 | 145 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2007 | 62 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2006 | 12 | 0.020 |
Why?
|
Transcriptional Activation | 1 | 2006 | 42 | 0.020 |
Why?
|
Organ Specificity | 1 | 2006 | 77 | 0.020 |
Why?
|
United States | 1 | 2015 | 3630 | 0.020 |
Why?
|
Dexamethasone | 1 | 2006 | 42 | 0.020 |
Why?
|
Lung | 1 | 2008 | 233 | 0.020 |
Why?
|
Ovary | 1 | 2006 | 54 | 0.020 |
Why?
|
Granulosa Cells | 1 | 2005 | 11 | 0.020 |
Why?
|
DNA Repair | 1 | 2005 | 50 | 0.020 |
Why?
|
Estrogens | 1 | 2005 | 162 | 0.020 |
Why?
|
Collagen Type II | 1 | 2003 | 8 | 0.010 |
Why?
|
Viscera | 1 | 2003 | 17 | 0.010 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 14 | 0.010 |
Why?
|
Osteonectin | 1 | 2003 | 16 | 0.010 |
Why?
|
tau Proteins | 1 | 2003 | 38 | 0.010 |
Why?
|
Transcription Factors | 1 | 2003 | 172 | 0.010 |
Why?
|
Fluorescent Antibody Technique, Indirect | 1 | 2001 | 12 | 0.010 |
Why?
|
Biological Therapy | 1 | 2001 | 20 | 0.010 |
Why?
|
Neurons | 1 | 2003 | 394 | 0.010 |
Why?
|
Apoptosis | 1 | 2001 | 337 | 0.010 |
Why?
|